In 2014, the VA and DoD published a CPG for the Management of Dyslipidemia for Cardiovascular Risk Reduction (2014 VA/DoD Dyslipidemia CPG), which was based on evidence reviewed from January 2010 through February 2014. Since then, a growing body of research has expanded the general knowledge and understanding of dyslipidemia and cardiovascular (CV) risk. Consequently, a recommendation to update the 2014 VA/DoD Dyslipidemia CPG was initiated in 2019. The system-wide goal of evidence-based guidelines is to improve the patient s health and well-being. To that end, this CPG is intended to guide providers who care for patients with dyslipidemia along management pathways supported by evidence. The expected outcomes of successful implementation of this guideline include: Emphasizing the use of patient-centered care using risk factors and event history Minimizing preventable complications and morbidity Optimizing each individual s health outcomes and improving quality of life Assessing the patient s condition and collaborating with the patient, family, and caregivers to determine the optimal treatment II. Dyslipidemia is Defined by Risk for Cardiovascular Disease Cardiovascular diseasea (CVD) is a major cause of morbidity and mortality in the United States (U.S.) and globally.[2,3] Most CVD is caused by atherosclerosis, which is the buildup of plaque (i.e., cholesterol, proteins, calcium, and inflammatory cells) in the walls of arteries. This plaque can narrow the lumen of arteries, limiting the flow of oxygenated blood and increasing the risk of chronic and acute ischemia. If a plaque ruptures within a vital artery, a blood clot forms and may obstruct the flow of oxygenated blood to the heart or brain, resulting in an acute coronary syndrome (ACS), myocardial infarction (MI), or stroke, with potentially irreversible damage to the tissue of the heart or brain. 